Advertisement

Topics

MediGene AG MDG1 Financial and Strategic SWOT Analysis Review [Report Updated: 28062017] Prices from USD $125

10:55 EDT 3 Jul 2017 | BioPortfolio Report Blog

MediGene AG MDG1 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.

Highlights

MediGene AG MediGene is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and preclinical development. The company focuses on the development of personalized Tcellbased immunotherapies. Its core business develops three immunotherapy platforms such as DC vaccines to kill tumor cells; Tcell receptor TCR detect and efficiently kill tumor cells and Tcellspecific monoclonal antibodies TAB's, helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.

MediGene AG Key Recent Developments

May 11,2017: Medigene Reports Results Of First Quarter 2017
May 11,2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role
Mar 23,2017: Medigene publishes its 2016 annual report and outlook for 2017
Nov 22,2016: Medigene appoints Dr. Thomas Taapken as Chief Financial Officer
Nov 16,2016: Medigene highlights a new approach for neoantigenspecific TCRs at Neoantigen Summit 2016 in Boston

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: MediGene AG MDG1 Financial and Strategic SWOT Analysis Review [Report Updated: 28062017] Prices from USD $125

NEXT ARTICLE

More From BioPortfolio on "MediGene AG MDG1 Financial and Strategic SWOT Analysis Review [Report Updated: 28062017] Prices from USD $125"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...